Thermogenesis Holdings Inc 最大收入来源是 Device- Automated Cell Separation System,在最近的收益报告中收入为 4,970,000。就地区而言, United States 是 Thermogenesis Holdings Inc 的主要市场,收入为 6,029,000。
Thermogenesis Holdings Inc 是否盈利?
否,根据最新的财务报表,Thermogenesis Holdings Inc 的净亏损为 $0
Thermogenesis Holdings Inc 有负债吗?
否,Thermogenesis Holdings Inc 的负债为 0
Thermogenesis Holdings Inc 的流通股有多少?
Thermogenesis Holdings Inc 的总流通股为 0
关键数据
前收盘价
$0.0001
开盘价
$0.0001
当日区间
$0.0001 - $0.0001
52周范围
$0 - $0.0001
交易量
100
平均成交量
1.2K
股息收益率
--
每股收益(TTM)
-5.00
市值
$1.5K
什么是 THMO?
ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. The company is headquartered in Rancho Cordova, California and currently employs 25 full-time employees. The firm provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The firm markets and sells its medical device products through independent distributors.